TLR7 and neoplasm: The researchers found that in the B16F10 melanoma model, intratumorally administered formalin-inactivated CPMV suppressed tumor growth, prolonged mouse survival, and activated Toll-like receptor 7/8 signaling to reprogram the tumor microenvironment (TME) from immunosuppressive to immunostimulatory, thereby amplifying systemic anti-tumor immunity.